Is There a Response of Glaucoma to Baduanjin Exercise in Elders?

September 2, 2025 updated by: Ali Mohamed Ali ismail, Cairo University
glaucoma is prevalent between elders. Baduanjin exercise is a suitable exercise for elders. elders with glaucoma will divided to group I or group II. each/every group will contain 30 elders. group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks. group II will act as waistlist.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Baduanjin exercise is a suitable exercise for elders. elders with glaucoma will divided to group I or group II. each/every group will contain 30 elders. group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks. group II will act as waistlist.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
    • Dokki
      • Giza, Dokki, Egypt
        • Recruiting
        • Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • high-tension primary open angle glaucoma (bilateral)
  • ocular hypertension in both eyes

Exclusion Criteria:

  • cataract
  • diabetes
  • cardiac disorders
  • obesity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group number 1
group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks.
Behavioral: Baduanjin exercise
group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks.
No Intervention: group number 2
group II will act as waistlist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intraocular pressure
Time Frame: it will be measured after 8 weeks
it will be assessed in both eyes
it will be measured after 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
patient health questionnaire
Time Frame: it will be measured after 8 weeks
it is nine-item questionnaire assessing depression
it will be measured after 8 weeks
National Eye Institute Visual Function Questionnaire
Time Frame: it will be measured after 8 weeks
it is 25-item questionnaire
it will be measured after 8 weeks
Glaucoma-related quality of life questionnaire
Time Frame: it will be measured after 8 weeks
it is a quality of life questionnaire
it will be measured after 8 weeks
State trait anxiety inventory
Time Frame: it will be measured after 8 weeks
it is a questionnaire about anxiety
it will be measured after 8 weeks
Stress vulnerability scale
Time Frame: it will be measured after 8 weeks
it is a questionnaire about Stress vulnerability
it will be measured after 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Principal Investigator: Ali MA Ismail, lecturer, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2025

Primary Completion (Estimated)

October 1, 2025

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

September 2, 2025

First Submitted That Met QC Criteria

September 2, 2025

First Posted (Estimated)

September 9, 2025

Study Record Updates

Last Update Posted (Estimated)

September 9, 2025

Last Update Submitted That Met QC Criteria

September 2, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB00014233-35

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe